Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.38 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.38 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3286759 | 1.00 | KMT2A (0.41) | KMT2AKDM4EALDH1A1LMNAMEN1 | |
| SCHEMBL3286762 | 1.00 | KMT2A (0.41) | KMT2AKDM4EALDH1A1LMNAMEN1 | |
| SCHEMBL3289203 | 0.93 | KDM4E (0.46) | KMT2AKDM4EALDH1A1LMNAMEN1 | |
| SCHEMBL3289196 | 0.93 | KDM4E (0.46) | KMT2AKDM4EALDH1A1LMNAMEN1 | |
| SCHEMBL3289194 | 0.93 | KDM4E (0.46) | KMT2AKDM4EALDH1A1LMNAMEN1 | |
| SCHEMBL3290945 | 0.91 | KMT2A (0.44) | KMT2AKDM4EALDH1A1LMNAMEN1 | |
| SCHEMBL3290949 | 0.91 | KMT2A (0.44) | KMT2AKDM4EALDH1A1LMNAMEN1 | |
| SCHEMBL3290953 | 0.91 | KMT2A (0.44) | KMT2AKDM4EALDH1A1LMNAMEN1 | |
| SCHEMBL3295195 | 0.90 | KDM4E (0.47) | KMT2AKDM4EALDH1A1MEN1MAPT | |
| SCHEMBL3295193 | 0.90 | KDM4E (0.47) | KMT2AKDM4EALDH1A1MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2207540-B1 | CYCLOPROPYL ARYL AMIDE DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2014-02-26 | — | — | EP | claimed |
| US-7723391-B2 | Cyclopropyl aryl amide derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2010-05-25 | — | — | US | claimed |
| EP-2207540-B1 | CYCLOPROPYL ARYL AMIDE DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2014-02-26 | — | — | EP | disclosed |
| CN-101815512-B | Cyclopropyl aryl amide derivatives and uses thereof | HOFFMANN LA ROCHE | 2013-04-24 | — | — | CN | disclosed |
| CN-101815512-A | cyclopropyl aryl amide derivatives and uses thereof | HOFFMANN LA ROCHE | 2010-08-25 | — | — | CN | disclosed |
| US-7723391-B2 | Cyclopropyl aryl amide derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090093525-A1 | Cyclopropyl aryl amide derivatives and uses thereof | ROCHE PALO ALTO LLC | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093525-A1 | Cyclopropyl aryl amide derivatives and uses thereof | AR, ADRA2A, ADRA1A | KMT2A 2189/4885KDM4E 3029/4885ALDH1A1 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.